Clinical Trial

A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression

Study acronym: BORDEAUX-GLIO
Recruiting
View on ClinicalTrials.gov →
Summary
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-08-08
notable Primary completion pushed: 2030-12 -> 2031-10 2026-08-08
minor Completion pushed: 2030-12 -> 2031-10 2026-08-08
Trial Details
NCT Number NCT07173829
Lead Sponsor University Hospital, Bordeaux
Collaborators: University of Bordeaux
Conditions Glioblastoma
Enrollment 45 participants
Start Date 2025-10-22
Primary Completion 2031-10 (estimated)
Study Completion 2031-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-07